Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
19 Octobre 2023 - 12:00PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today announced that it will release financial and
operational results for the third quarter of 2023, on Thursday,
November 2, 2023, before markets open. Aurinia’s management team
will host a conference call/webcast at 8:30 am ET that day to
review these results and provide a general business update.
Interested participants can dial (888) 645-4404 / (862) 298-0702
(Toll-free U.S. & Canada). The audio webcast can also be
accessed under "News/Events” through the “Investors” section of the
Aurinia corporate website at www.auriniapharma.com. A replay of the
webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations with high unmet medical needs that are impacted by
autoimmune, kidney, and rare diseases. In January 2021, the Company
introduced LUPKYNIS® (voclosporin), the first FDA-approved oral
therapy dedicated to the treatment of adult patients with active
lupus nephritis. The Company’s head office is in Edmonton, Alberta,
its U.S. commercial office is in Rockville, Maryland. The Company
focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019615230/en/
Investor/Media: ir@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
